NCT05645302

Intensive Monitoring Scheme of Lidocaine Cataplasms

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Qianfoshan Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively. Taking the time when the patient first used Lidocaine Cataplasms as the starting time (the study baseline), collect the demographic characteristics of the patient, the medication scheme of Lidocaine Cataplasms and other information, as well as the medication safety and other information from the first medication to the end of medication or discharge (whichever occurs first).

Conditions

• Adverse Reaction to Drug

Interventions

Type	Name	Description
DRUG	Lidocaine Cataplasms	The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.

Timeline

• Start date: 2022-04-06
• Primary completion: 2022-10-31
• Completion: 2022-12-31
• First posted: 2022-12-09
• Last updated: 2022-12-09

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study